BriaCell Therapeutics Corp (BCTXW)
$0.00
$0.00
(-57.14%)
As on 06-Mar-2026 09:30EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
10 Years Aggregate
CFO
$-56.85 Mln
EBITDA
$-23.84 Mln
Net Profit
$-46.83 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
BriaCell Therapeutics Corp (BCTXW)
| -98.3 | -89.9 | -98.0 | -99.1 | -93.4 | -74.9 | -- |
|
BSE Sensex*
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
BriaCell Therapeutics Corp (BCTXW)
| -81.8 | -88.2 | 21.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout BriaCell Therapeutics Corp (BCTXW)
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that... is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada. Read more
-
CEO, President & Director
Dr. William V. Williams M.D.
-
CEO, President & Director
Dr. William V. Williams M.D.
-
Headquarters
West Vancouver, BC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for BriaCell Therapeutics Corp (BCTXW)
What is the current share price of BriaCell Therapeutics Corp (BCTXW) Today?
The share price of BriaCell Therapeutics Corp (BCTXW) is $0.00 (NASDAQ) as of 06-Mar-2026 09:30 EDT. BriaCell Therapeutics Corp (BCTXW) has given a return of -93.39% in the last 3 years.
What is the current PB & PE ratio of BriaCell Therapeutics Corp (BCTXW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-- |
-- |
2024 |
-- |
-- |
2023 |
-1.97 |
-10.58 |
2023 |
-- |
-- |
2022 |
-2.76 |
3.09 |
What is the 52 Week High and Low of BriaCell Therapeutics Corp (BCTXW)?
The 52-week high and low of BriaCell Therapeutics Corp (BCTXW) are Rs 0.25 and Rs 0.00 as of 02-Sep-2026.
What is the market cap of BriaCell Therapeutics Corp (BCTXW)?
BriaCell Therapeutics Corp (BCTXW) has a market capitalisation of $ 48 Mln as on 06-Mar-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in BriaCell Therapeutics Corp (BCTXW)?
Before investing in BriaCell Therapeutics Corp (BCTXW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.